

The risk factors associated with postoperative mediastinitis in cardiac surgery: a systematic review and meta-analysis

*Kalp cerrahisinde ameliyat sonrası mediastinitle ilişkili risk etkenleri:
Sistemik derleme ve meta analiz*

Selen Öztürk,¹ İbrahim Öztürk,² Seher İlhan³

Institution where the research was done:

Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey

Author Affiliations:

¹Department of Cardiovascular Surgery, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey

²Department of Anaesthesiology and Reanimation, Göztepe Training and Research Hospital, İstanbul, Turkey

³Department of Anaesthesiology and Reanimation, Medical Faculty of Uludağ University, Bursa, Turkey

ABSTRACT

Background: In this review, we aimed to analyze the risk factors of mediastinitis after open cardiac surgery.

Methods: The literature screening was performed at Pubmed, Ovid, and Sciencedirect databases without date limitation. Studies investigating the co-existing diseases were included. The results of trials were evaluated with random or fixed effect model according to the heterogeneity.

Results: A total of 5009 articles were attained after database searching. Thirty five articles were included to the meta-analysis including 131.158 patients who met inclusion criteria. The most possible preoperative risk factors for mediastinitis were atrial fibrillation, pulmonary disease, diabetes mellitus, renal disease, peripheral vascular disease and systemic hypertension ($p<0.05$). Pulmonary hypertension, malignancy, hepatic and neurological diseases, heart failure and dyslipidemia were not found to be risk factors ($p>0.05$). Heterogeneity was not observed for four (renal, hepatic, neurological and peripheral vascular diseases) of 12 factors ($I^2<25\%$).

Conclusion: The results of our meta-analysis showed that preoperative co-existing diseases such as pulmonary hypertension, malignancy, heart failure, hepatic and neurological diseases, and dyslipidemia may not be risk factors for the development of mediastinitis following cardiac surgery.

Keywords: Cardiac surgery; mediastinitis; risk factor.

ÖZ

Amaç: Bu derlemede, açık kalp cerrahisinden sonra mediastinitin risk etkenleri analiz edildi.

Çalışma planı: Literatür taraması tarih sınırlaması olmadan Pubmed, Ovid ve Sciencedirect veritabanlarında uygulandı. Eş zamanlı hastalıkları araştıran çalışmalar dahil edildi. Çalışma bulguları heterojenite durumuna göre rastgele ya da sabit etki modeli ile değerlendirildi.

Bulgular: Veritabanı taramasından sonra toplam 5009 makale elde edildi. Dahil edilme kriterlerini karşılayan 131.158 hastanın yer aldığı 35 makale meta analize dahil edildi. Mediastinit için en olası ameliyat öncesi risk etkenleri atriyal fibrilasyon, pulmoner hastalık, diabetes mellitus, renal hastalık, periferik damar hastalığı ve sistemik hipertansiyon idi ($p<0.05$). Pulmoner hipertansiyon, malignite, hepatik ve nörolojik hastalıklar, kalp yetmezliği ve dislipidemi risk etkeni olarak bulunmadı ($p>0.05$). Heterojenite 12 etkenin dördünde (renal, hepatik, nörolojik ve periferik damar hastalıkları) gözlenmedi ($I^2<25\%$).

Sonuç: Meta analiz sonucu pulmoner hipertansiyon, malignite, kalp yetmezliği, hepatik ve nörolojik hastalıklar ve dislipidemi gibi ameliyat öncesi eş zamanlı hastalıkların kalp cerrahisinden sonra mediastinit gelişimi için risk etkeni olmadığını gösterdi.

Anahtar sözcükler: Kalp cerrahisi; mediastinit; risk etkeni.



Available online at
www.tgkdc.dergisi.org
doi: 10.5606/tgkdc.dergisi.2015.10754
QR (Quick Response) Code

Received: August 06, 2014 Accepted: September 22, 2014

Correspondence: Selen Öztürk, M.D. Dışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi, Kalp ve Damar Cerrahisi Kliniği, 06330 Dışkapı, Ankara, Turkey.

Tel: +90 312 - 596 20 00 e-mail: drselen1980@gmail.com

Mediastinitis, also known as deep sternal wound infection (DSWI), is a rare, serious complication often seen after open cardiac surgery which may increase the length of intensive care unit (ICU) and/or hospital stays and also may cause a higher mortality rate. Researchers have reviewed the preoperative, intraoperative and postoperative variables for predicting postoperative mediastinitis development,^[1-5] and coexisting diseases, such as diabetes mellitus (DM) and systemic hypertension (HT) along with pulmonary, renal, hepatic, and neurological diseases, were generally examined in those studies. However, we found controversy regarding the association between postoperative mediastinitis and those diseases. Therefore, in this study, we aimed to review and analyze the literature to determine which preoperative variables can be used to predict mediastinitis.

MATERIALS AND METHODS

Search strategy

We performed the database search and analyzed the article in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).^[6] Two authors searched the PubMed electronic database to determine whether or not coexisting diseases could predict the development of mediastinitis after cardiac surgery. The search concluded on January 5th, 2014, and there were no limitations related to this date.

The search was conducted using the following English keywords or a combination of these words: cardiac surgery, heart surgery, valve surgery, coronary artery bypass grafting (CABG), mediastinitis, and DSWI. The search was limited to English, with articles in other languages being excluded from the study. In addition, the study was limited to clinical trials, comparative studies, multicenter studies, observational studies, randomized controlled trials, controlled clinical trials, and evaluation studies.

Selection of studies

The studies, regardless of sample size, included both retrospective and prospective clinical studies. Inclusion criteria were that it was a clinical study that involved open cardiac surgery with off-pump or extracorporeal circulation and that the article was in English. Experimental studies, articles not in English, and those that focused on non-cardiac surgery were excluded from the study. Furthermore, articles that were associated with our review topic but did not contain information concerning the rate of mediastinitis

according to preoperative coexisting diseases were also excluded as well as those that contained data with figures but no numerical values.

Data extraction

Two reviewers independently extracted data from the relevant studies, and any disagreements were resolved by consensus using a third reviewer. At first, we gathered the publication information (first author's name, publication year, patient population, and type of surgery), characteristics of the participants (sample size and type of study methods), and outcome information (mediastinitis rate, number of diseases, number of control cases, and definition of mediastinitis) and then recorded the number of patients with and without mediastinitis (controls).

Statistical analysis

Statistical analysis was carried out using the Comprehensive Meta-Analysis (CMA) Version 2.0 (Biostat, Englewood, New Jersey, USA), and the odds ratio (OR) and 95% confidence interval (CI) (lower-upper limit) was utilized for this analysis. The heterogeneity was evaluated using the statistics of I^2 , with it being accepted as significant if $I^2 > 25%$. In addition, the heterogeneity was classified as low ($25% < I^2 < 50%$), moderate ($50% < I^2 < 75%$), or high




Figure 1. Flow diagram of database search.

Table 1. Studies included in the analysis

References	Risk factors in each study	Mediastinitis/control (n)	LE
Abboud et al. ^[7]	MA: Obesity, smoking, intensive care unit stay of >2 days, infection at another site	39/78	3b
Antunes et al. ^[2]	Higher incidence of obesity, diabetes, peripheral vascular disease	60/2,452	2b
Ashley et al. ^[8]	MA: Diabetes, female gender, age >70 years	143/80	3b
Baillot et al. ^[9]	Significant differences between groups: BMI, diabetes, COPD, renal disease	267/23,232	3b
Bitkover et al. ^[11]	MA: BMI, use of beta-adrenergic drug before onset of infection	37/74	2b
Braxton et al. ^[10]	Significant differences between groups: BMI, COPD, renal disease, HF, peripheral vascular disease	193/15,213	3b
Colombier et al. ^[11]	MA: Smoking, obesity, diabetes	74/148	2b
Dial et al. ^[12]	UA: Obesity, re-exploration	11/33	3b
Diez et al. ^[13]	MA: Obesity, COPD, BITA	45/1,643	3b
Eklund et al. ^[14]	MA: Age, gender, operation type, perfusion time	115/10,598	2b
Elenbaas et al. ^[15]	UA: Age, diabetes, BMI, atrial fibrillation, peripheral vascular disease, COPD, MA: Age, BMI, atrial fibrillation, diabetes, peripheral vascular disease	100/11,648	2b
Filsoufi et al. ^[16]	MA: Obesity, previous myocardial infarction, diabetes, COPD, preoperative length of stay >3 days, aortic calcification, aortic surgery, combined procedures, CPB time, re-exploration for bleeding, respiratory failure	106/5,692	3b
Floros et al. ^[5]	Significant differences between groups: Diabetes, previous surgery, BMI, emergency surgery	34/5,615	2b
Ghotaslou et al. ^[17]	Significant difference between groups: Mean blood transfusion units, obesity, reoperation, diabetes, HF, hospitalization more than 3 days before surgery	23/1,804	3b
Gualis et al. ^[18]	MA: Respiratory failure, intensive care unit stay	22/816	2b
Gummert et al. ^[19]	UA: Diabetes, intensive care unit stay >5 days, mechanical ventilation >72 hours, reexploration, IABP MA: BMI, IABP, diabetes, intensive care unit stay >5 days	134/9,169	2b
Hallam et al. ^[20]	Significant difference between groups: Smoking, BMI, diabetes	53/7,530	3b
Lin et al. ^[21]	UA: Previous hospitalization, re-sternotomy, chronic renal disease, longer operation time, postoperative HF, postoperative renal failure, reoperation MA: Previous hospitalization, reoperation	48/65	3b
Lopez Gude et al. ^[22]	MA: Obesity, diabetes, COPD, preoperative stay >1 week, pulmonary hypertension, reoperation, myocardial infarction	163/326	3b
Manganas et al. ^[23]	NS	4/322	3b
Munoz et al. ^[24]	UA: Emergency surgery, NYHA class IV, CABG, heart transplantation, MA: Reoperation, vasoactive drugs, CABG	73/73	3b
Newman et al. ^[25]	UA: COPD, prior sternotomy, pyuria, low ejection fraction, high left ventricular end diastolic pressure (preoperative variables) Logistic regression: COPD, duration of surgery, longer postoperative mechanical ventilation	68/136	3b
Omran et al. ^[26]	MA: Hypertension, re-exploration, female gender	44/9,157	2b
Parissis et al. ^[4]	MA: Diabetes, preoperative creatinine >200 µmol/L, prolonged ventilation	52/3,896	2b
Ridderstolpe et al. ^[27]	MA: Obesity, diabetes, smoking, peripheral vascular disease, high NYHA score	291/2,717	3b

Table 1. (continued)

References	Risk factors in each study	Mediastinitis/control (n)	LE
Rishnes et al. ^[31]	MA: Age >70 years, male gender, left main stenosis, body mass index ≥30, COPD, diabetes, blood transfusion	107/444	3b
Robinson et al. ^[28]	MA: Type of surgery, diabetes, preoperative dialysis, respiratory disease, body mass index, ventricular assist device, BITA	153/11,695	3b
Rosmarakis et al. ^[29]	This study contained only one case of mediastinitis	1/342	2b
Sa et al. ^{[30]*}	MA: Obesity, diabetes, smoking, pedicled internal thoracic artery, CPB	28/500	3b
Sa et al. ^{[31]**}	UA: Use of pedicled internal thoracic artery, postoperative renal complications, re-operation	11/157	3b
Sakamoto et al. ^[32]	UA: IABP, emergency operation, operation time >8 hours, intensive care unit stay >5 days, postoperative hyperglycemia		
San Juan et al. ^[33]	MA: Combined CABG, postoperative use of IABP	17/846	3b
Stahle et al. ^[34]	Significant difference between groups: COPD UA: Female gender, age, diabetes, hypertension, postoperative renal dialysis, BITA	17/51	3b
Tiveron et al. ^[35]	MA: Female gender, diabetes, postoperative renal dialysis, BITA	28/528	2b
Wouters et al. ^[36]	MA: Intraaortic balloon pump, hemodialysis, extracardiac vascular intervention UA: Perfusion time, mechanical ventilation >72 hours, length of stay in operating room >5.5 hours MA: Diabetes, smoking, reoperation, mechanical ventilation >72 hours	35/2,733	2b
		23/1,345	3b

LE: Levels of evidence; MA: Multivariate analysis; BMI: Body mass index; COPD: Chronic obstructive pulmonary disease; HF: Heart failure; UA: Univariate analysis; BITA: Bilateral internal thoracic artery graft; CPB: Cardiopulmonary bypass; IABP: Intra aortic balloon pump; NS: Not Significant; NYHA: New York Heart Association; CABG: Cardiopulmonary Artery Bypass Grafting.

(I² >75%) and was evaluated by analyzing subgroups and moderators. The meta-analysis was performed by using fixed or random effect models, with the latter being conducted in the presence of heterogeneity (I² >25%) and the former without heterogeneity (I² <25%). The overall effect was analyzed via a Z score, and potential publication bias was evaluated using the Begg test.

RESULTS

A flow diagram of the database search is shown in Figure 1. We identified 5,009 records and filtered these down to 999 articles. After duplicates were removed, 374 records remained, and 255 of these were excluded after screening because they were deemed to be unrelated to our topic. Then the full text of 119 articles were assessed for their eligibility, and 83 were excluded because of the absence of detailed data regarding gender in each group. This left 36 articles that were included in the quantitative synthesis.^[1-5,7-36] The demographic features of these studies are summarized in Table 1. The ratio of development of mediastinitis was 1.99% (2,619 cases out of 131,158). Results of analysis, heterogeneity and publication bias are shown in Table 2-14.

DISCUSSION

Cardiac surgery is special because of both the individual properties of the patients and the operative procedures. Advanced age and coexisting diseases are common causes of morbidity, with invasive interventions [e.g., arterial cannulation, central venous catheterization, cardiopulmonary bypass (CPB), intra-aortic balloon pumps (IABPs), blood transfusions, and ICU stays being other possible sources of infection. In addition, invasive interventions may lead to the entry of bacterial pathogens.^[37]

Kansy et al.^[38] found that the ratio of major infections (septicemia, endocarditis, and mediastinitis) was 3.1% after cardiac surgery, and Chen et al.^[39] also found a similar ratio for major infections (3.2%), with the risk factors being a high body mass index (BMI), previous CABG, emergency surgery, renal impairment, heart failure, peripheral and cerebrovascular diseases, and immunosuppression.

Many of the coexisting diseases, such as DM,^[40] heart failure,^[41] pulmonary disease,^[23] and malignancy,^[42] may decrease a patient’s resistance against infection while longer treatment durations of other conditions (AF and systemic HT) can increase the duration of ICU and hospital stays. Hence, the possibility of infection is also higher.

Table 2. Results of analysis

Variables	Results of analysis					Heterogeneity				Publication bias
	OR	95% CI		Z value	p	Q value	df	p	I ²	tau ²
Pulmonary hypertension	1.9	0.8	4.64	1.52	0.12	5.68	2	0.05	64.7	0.35
Malignancy	2.3	0.3	17.2	0.81	0.4	1.68	1	0.1	40.7	1.06
Hepatic disease	2.8	0.6	12.5	1.3	0.16	1.04	3	0.7	0.0	0.0
Dyslipidemia	1.1	0.7	1.6	0.6	0.5	5.2	3	0.5	43.11	0.07
Neurological disease	1.3	0.9	1.8	1.5	0.12	1.14	2	0.5	0.0	0.0
Atrial fibrillation	2.9	1.0	8.0	2.0	0.03	7.36	2	0.02	72.84	0.55
Peripheral vascular disease	1.7	1.4	2.0	5.7	0.0	10.7	9	0.2	16.57	0.01
Heart failure	1.1	0.8	1.7	0.9	0.3	63.7	11	0.0	82.73	0.3
Renal disease	1.9	1.5	2.3	6.1	0.0	19.2	15	0.2	22.12	0.06
Systemic hypertension	1.3	1.0	1.6	2.2	0.02	25.09	14	0.03	44.21	0.08
Diabetes mellitus	2.1	1.8	2.4	11.0	0.0	38.87	27	0.06	30.54	0.03
Pulmonary disease	2.4	1.8	3.1	6.2	0.0	79.79	25	0.0	68.67	0.26

OR: Odds ratio; CI: Confidence interval; p<0.05 is evaluated as significant; I²: <25% is accepted as no heterogeneity; df: degree of freedom; tau²: <0.05 is evaluated as significant.

In our meta-analysis, some of the diseases occurred less frequently. Three studies featured pulmonary HT, two focused on malignancy, four had cases of hepatic disease, four included patients with dyslipidemia, three featured neurological disease, and three had cases of AF. The most studied diseases were DM (29 studies), renal

disease (16 studies), systemic HT (15 studies), heart failure (12 studies), and peripheral vascular disease (10 studies). We did not observe heterogeneity for the studies that focused on peripheral vascular and renal disease (I² <25%). Furthermore, the heterogeneity of the studies that featured DM and systemic HT was low (25% < I² < 50%), but it was

Table 3. Pulmonary hypertension and mediastinitis

Study name	Statistics for each study					Odds ratio and 95% CI	Relative weight
	Odds ratio	Lower limit	Upper limit	Z value	p		
San Juan et al. ^[33]	3.429	0.622	18.908	1.414	0.157		17.41
López Gude et al. ^[22]	2.903	1.706	4.939	3.931	0.000		
Tiveron et al. ^[35]	0.940	0.425	2.079	-0.153	0.879		
	1.961	0.827	4.649	1.529	0.126		

CI: Confidence interval; OR: 1.96, 95% CI: 0.82-4.64; Z value=1.52, p=0.12. Heterogeneity: Q value=5.68, df: 2, p=0.05, I²: 64.7%.

Table 4. Malignancy and mediastinitis

Study name	Statistics for each study					Odds ratio and 95% CI	Relative weight
	Odds ratio	Lower limit	Upper limit	Z value	p		
Lin et al. ^[21]	0.443	0.018	11.120	-0.495	0.621		27.96
Colombier et al. ^[11]	4.364	1.269	15.005	2.338	0.019		
	2.303	0.308	17.210	0.813	0.416		

CI: Confidence interval; OR: 2.3; 95% CI: 0.3-17.2; Z value=0.81; p=0.4; heterogeneity: Q value=1.68; df: 1; p=0.19; I²: 40.7%.

Table 5. Hepatic disease and mediastinitis

Study name	Statistics for each study					Odds ratio and 95% CI	Relative weight
	Odds ratio	Lower limit	Upper limit	Z value	<i>p</i>		
Dodds Ashley et al. ^[8]	1.695	0.068	42.089	0.322	0.748		21.27
Newman et al. ^[25]	10.263	0.486	216.814	1.496	0.135		23.59
Tiveron et al. ^[35]	3.066	0.178	52.802	0.772	0.440		27.10
Lin et al. ^[21]	1.362	0.083	22.331	0.216	0.829		28.05
	2.862	0.651	12.592	1.391	0.164		

CI: Confidence interval; OR: 2.8; 95% CI: 0.6-12.5; Z value=1.3; *p*=0.16; heterogeneity: Q value=1.04; df: 3; *p*=0.78; I²: 0.0%.

Table 6. Dyslipidemia and mediastinitis

Study name	Statistics for each study					Odds ratio and 95% CI	Relative weight
	Odds ratio	Lower limit	Upper limit	Z value	<i>p</i>		
Salehi Omran et al. ^[26]	1.236	0.662	2.308	0.665	0.506		24.03
Colombier et al. ^[11]	0.805	0.460	1.409	-0.759	0.448		27.21
Abboud et al. ^[7]	2.368	1.074	5.223	2.137	0.033		17.74
Risnes et al. ^[3]	0.951	0.582	1.555	-0.198	0.843		31.01
	1.138	0.764	1.697	0.636	0.525		

CI: Confidence interval; OR: 1.13; 95% CI: 0.7-1.6; Z value=0.6; *p*=0.5; heterogeneity: Q value=5.2; df: 3; *p*=0.5; I²: 43.11%.

Table 7. Neurological disease and mediastinitis

Study name	Statistics for each study					Odds ratio and 95% CI	Relative weight
	Odds ratio	Lower limit	Upper limit	Z value	<i>p</i>		
Tiveron et al. ^[35]	1.234	0.374	4.066	0.345	0.730		8.73
Filsoufi et al. ^[16]	1.702	0.945	3.066	1.771	0.077		35.85
Robinson et al. ^[28]	1.131	0.704	1.815	0.508	0.612		55.41
	1.319	0.927	1.876	1.540	0.123		

CI: Confidence interval; OR: 1.3; 95% CI: 0.9-1.8; Z value=1.5; *p*=0.12; heterogeneity: Q value=1.14; df: 2; *p*=0.56; I²: 0.00%.

Table 8. Atrial fibrillation and mediastinitis

Study name	Statistics for each study					Odds ratio and 95% CI	Relative weight
	Odds ratio	Lower limit	Upper limit	Z value	<i>p</i>		
Gualis et al. ^[18]	2.167	0.488	9.628	1.016	0.310		23.29
Risnes et al. ^[3]	1.550	0.670	3.584	1.025	0.305		35.83
Elenbaas et al. ^[15]	6.111	3.371	11.078	5.965	0.000		40.88
	2.936	1.073	8.033	2.097	0.036		

CI: Confidence interval; OR: 2.9; 95% CI: 1.0-8.0; Z value=2.0; *p*=0.03; heterogeneity: Q value=7.36; df: 2; *p*=0.02; I²: 72.84%.

Table 9. Peripheral vascular disease and mediastinitis

Study name	Statistics for each study					Odds ratio and 95% CI	Relative weight
	Odds ratio	Lower limit	Upper limit	Z value	p		
Diez et al. ^[13]	1.199	0.501	2.870	0.407	0.684		4.25
Elenbaas et al. ^[15]	2.230	1.395	3.565	3.350	0.001		14.73
Filsouf et al. ^[16]	1.627	0.962	2.752	1.815	0.070		11.73
López Gude et al. ^[22]	1.896	1.045	3.440	2.104	0.035		9.13
Ridderstolpe et al. ^[27]	1.566	1.030	2.380	2.097	0.036		18.46
Antunes et al. ^[2]	3.171	1.406	7.155	2.780	0.005		4.89
Parissis et al. ^[4]	0.934	0.453	1.925	-0.184	0.854		6.20
Salehi Omran et al. ^[26]	1.267	0.173	9.258	0.234	0.815		0.82
San Juan et al. ^[33]	6.409	1.541	26.657	2.555	0.011		1.60
Braxton et al. ^[10]	1.550	1.105	2.176	2.535	0.011		28.19
	1.702	1.421	2.037	5.787	0.000		

CI: Confidence interval; OR: 1.7; 95% CI: 1.4-2.0; Z value=5.7; p=0.00; heterogeneity: Q value=10.7; df: 9; p=0.2; I²: 16.57%.

high for those that included patients with heart failure (I² >75%).

The ratio of mediastinitis development was approximately 2%. However, future studies are needed because only nine of the 35 studies had a large sample size (>5,000) (23,499 in Baillot et al.,^[9] 15,406 in Braxton et al.,^[10] 11,848 in Robinson et al.,^[28] 11,748 in Elenbaas et al.,^[15] 10,713 in Eklund et

al.,^[14] 9,303 in Gummert et al.,^[19] 7,583 in Hallam et al.,^[20] 5,798 in Filsoufi et al.,^[16] and 5,649 in Floros et al.^[5] However, none of these included the majority of the factors we wanted to assess in their analyses. When we excluded^[5,9,10,14-16,19,20,28] those results from our analysis, the present results changed as opposite for pulmonary HT, hepatic and neurological disease, AF, and heart failure.

Table 10. Heart failure and mediastinitis

Study name	Statistics for each study					Odds ratio and 95% CI	Relative weight
	Odds ratio	Lower limit	Upper limit	Z value	p		
Tiveron et al. ^[35]	0.866	0.434	1.727	-0.409	0.682		8.55
Filsouf et al. ^[16]	1.615	1.094	2.383	2.413	0.016		10.54
Ghotaslou et al. ^[17]	3.154	1.155	8.619	2.240	0.025		6.52
Braxton et al. ^[10]	2.434	1.811	3.270	5.902	0.000		11.05
Eklund et al. ^[14]	0.960	0.661	1.394	-0.215	0.830		10.64
Muñoz et al. ^[24]	3.106	1.511	6.383	3.083	0.002		8.34
Sakamoto et al. ^[32]	1.461	0.534	3.996	0.738	0.460		6.52
Ridderstolpe et al. ^[27]	1.405	1.023	1.931	2.097	0.036		10.94
Abboud et al. ^[7]	0.216	0.095	0.490	-3.663	0.000		7.67
Diez et al. ^[13]	1.035	0.139	7.707	0.033	0.973		2.79
López Gude et al. ^[22]	0.616	0.412	0.920	-2.369	0.018		10.47
San Juan et al. ^[33]	0.788	0.261	2.374	-0.424	0.671		5.97
	1.199	0.817	1.760	0.929	0.353		

CI: Confidence interval; OR: 1.1; 95% CI: 0.8-1.7; Z value=0.9; p=0.3; heterogeneity: Q value=63.7; df: 11; p=0.00; I²: 82.73%.

Table 11. Renal disease and mediastinitis

Study name	Statistics for each study					Odds ratio and 95% CI	Relative weight
	Odds ratio	Lower limit	Upper limit	Z value	p		
Dodds Ashley et al. ^[18]	0.553	0.076	4.004	-0.586	0.558		1.12
Gualis et al. ^[18]	0.779	0.103	5.918	-0.241	0.809		1.07
Sakamoto et al. ^[32]	1.354	0.078	23.429	0.209	0.835		0.54
Tiveron et al. ^[35]	5.476	1.619	18.527	2.734	0.006		2.95
Lin et al. ^[21]	4.013	1.175	13.706	2.217	0.027		2.90
Abboud et al. ^[7]	2.721	0.687	10.772	1.426	0.154		2.31
Ridderstolpe et al. ^[27]	1.038	0.131	8.219	0.035	0.972		1.02
Filsoufi et al. ^[16]	0.650	0.284	1.489	-1.018	0.309		6.37
Diez et al. ^[13]	2.028	1.078	3.813	2.194	0.028		10.98
Sá et al. ^[30]	2.899	1.115	7.535	2.183	0.029		4.80
Robinson et al. ^[28]	2.888	1.335	6.248	2.693	0.007		7.35
Baillot et al. ^[9]	1.858	1.341	2.575	3.723	0.000		41.14
Braxton et al. ^[10]	3.007	1.433	6.314	2.910	0.004		7.96
Gummert et al. ^[19]	1.437	0.698	2.957	0.984	0.325		8.40
Hallam et al. ^[20]	0.677	0.042	11.044	-0.274	0.784		0.56
Sá et al. ^[31]	0.400	0.022	7.117	-0.624	0.533		0.53
	1.918	1.556	2.365	6.103	0.000		

CI: Confidence interval; OR: 1.9; 95% CI: 1.5-2.3; Z value=6.1; p=0.00; heterogeneity: Q value=19.2; df: 15; p=0.2; I²: 22.12%.

Table 12. Systemic hypertension and mediastinitis

Study name	Statistics for each study					Odds ratio and 95% CI	Relative weight
	Odds ratio	Lower limit	Upper limit	Z value	p		
Abboud et al. ^[7]	2.017	0.863	4.714	1.621	0.105		5.26
Colombier et al. ^[11]	1.218	0.655	2.263	0.623	0.534		7.80
Diez et al. ^[13]	1.073	0.474	2.428	0.169	0.865		5.55
Elenbaas et al. ^[15]	0.933	0.625	1.392	-0.341	0.733		11.51
Filsoufi et al. ^[16]	1.245	0.841	1.845	1.094	0.274		11.65
Ghotaslou et al. ^[17]	1.117	0.481	2.595	0.257	0.797		5.31
Gualis et al. ^[18]	0.886	0.374	2.095	-0.276	0.782		5.15
López Gude et al. ^[22]	1.617	1.108	2.362	2.488	0.013		11.93
Risnes et al. ^[3]	1.605	1.020	2.524	2.047	0.041		10.51
Sá et al. ^[30]	0.988	0.289	3.384	-0.019	0.985		2.97
Antunes et al. ^[2]	0.921	0.549	1.544	-0.313	0.754		9.38
Salehi Omran et al. ^[26]	10.121	3.618	28.310	4.410	0.000		3.96
Sakamoto et al. ^[32]	1.020	0.390	2.668	0.040	0.968		4.39
San Juan et al. ^[33]	1.483	0.493	4.463	0.701	0.483		3.56
Sá et al. ^[31]	0.537	0.061	4.727	-0.560	0.575		1.08
	1.313	1.040	1.657	2.291	0.022		

CI: Confidence interval; OR: 1.3; 95% CI: 1.0-1.6; Z value=2.2; p=0.02; heterogeneity: Q value=25.09; df: 14; p=0.03; I²: 44.21%.

Table 13. Diabetes mellitus and mediastinitis

Study name	Statistics for each study					Odds ratio and 95% CI	Relative weight
	Odds ratio	Lower limit	Upper limit	Z value	p		
Abboud et al. ^[7]	2.400	1.060	5.433	2.099	0.036		2.12
Antunes et al. ^[2]	3.087	1.830	5.208	4.225	0.000		4.24
Dodds Ashley et al. ^[8]	1.353	0.764	2.396	1.036	0.300		3.73
Bitkover and Gärdlund ^[1]	3.145	1.269	7.793	2.475	0.013		1.77
Braxton et al. ^[10]	1.482	1.104	1.990	2.615	0.009		8.05
Colombier et al. ^[11]	1.206	0.664	2.191	0.615	0.539		3.50
Dial et al. ^[12]	0.776	0.189	3.174	-0.354	0.724		0.79
Diez et al. ^[13]	1.829	1.010	3.310	1.994	0.046		3.53
Elenbaas et al. ^[15]	2.390	1.595	3.581	4.225	0.000		5.88
Filsoufi et al. ^[16]	2.233	1.514	3.293	4.050	0.000		6.14
Floros et al. ^[5]	1.898	0.923	3.905	1.741	0.082		2.60
Ghotaslou et al. ^[17]	8.950	3.897	20.555	5.166	0.000		2.06
Gualis et al. ^[18]	0.745	0.272	2.042	-0.572	0.567		1.47
Hallam et al. ^[20]	2.349	1.367	4.037	3.092	0.002		4.03
Lin et al. ^[21]	2.017	0.909	4.475	1.725	0.085		2.21
López Gude et al. ^[22]	2.308	1.488	3.580	3.737	0.000		5.33
Muñoz et al. ^[24]	2.738	0.817	9.171	1.633	0.102		1.06
Newman et al. ^[25]	2.153	0.813	5.702	1.542	0.123		1.56
Salehi Omran et al. ^[26]	2.842	1.556	5.191	3.397	0.001		3.45
Parissis et al. ^[4]	2.114	1.153	3.874	2.421	0.015		3.42
Ridderstolpe et al. ^[27]	2.227	1.694	2.927	5.741	0.000		8.54
Risnes et al. ^[3]	2.846	1.661	4.877	3.806	0.000		4.06
Robinson et al. ^[28]	2.561	1.623	4.040	4.042	0.000		5.08
Sá et al. ^[31]	2.839	1.284	6.279	2.577	0.010		2.22
Sakamoto et al. ^[32]	1.206	0.388	3.744	0.324	0.746		1.19
San Juan et al. ^[33]	1.436	0.379	5.440	0.532	0.594		0.88
Stähle et al. ^[34]	1.774	1.226	2.566	3.041	0.002		6.49
Tiveron et al. ^[35]	1.843	0.943	3.602	1.789	0.074		2.93
Wouters et al. ^[36]	2.652	1.030	6.825	2.022	0.043	1.65	
	2.119	1.862	2.411	11.385	0.000		

CI: Confidence interval; OR: 2.1; 95% CI: 1.8-2.4; Z value=11.3; p=0.00; heterogeneity: Q value=38.96; df: 28; p=0.08; I²: 28.10%.

We used the definition of mediastinitis, type of surgery, and study design as moderators to analyze the reason for heterogeneity and found that the heterogeneity did not change based on the definition of mediastinitis or type of surgery. However, study design was a primary cause of heterogeneity.

In the literature, there were many studies that discussed the presence of mediastinitis after cardiac surgery. However, the main limitation of our meta-analysis was that we excluded studies because of their design and the absence of needed data. Another limitation was that we excluded the patients' individual demographic characteristics, such as age

and gender, along with the intraoperative variables (e.g., the presence or absence of CPB and aortic cross-clamp time) because we focused on coexisting diseases.

Conclusion

The results of our meta-analysis showed that preoperative coexisting diseases, such as pulmonary HT, malignancy, heart failure, hepatic and neurological diseases, and dyslipidemia, may not be risk factors for the development of mediastinitis after cardiac surgery. However, there is still a need for large, randomized, controlled studies to decrease the heterogeneity of analysis.

Table 14. Pulmonary disease and mediastinitis

Study name	Statistics for each study					Odds ratio and 95% CI	Relative weight
	Odds ratio	Lower limit	Upper limit	Z value	p		
Lin et al. ^[21]	3.663	0.679	19.752	1.510	0.131		1.96
Abboud et al. ^[7]	3.167	0.507	19.792	1.233	0.218		1.73
Elenbaas et al. ^[15]	2.271	1.430	3.605	3.478	0.001		6.17
Robinson et al. ^[28]	1.696	1.163	2.472	2.747	0.006		6.55
Ghotaslou et al. ^[17]	0.892	0.207	3.837	-0.153	0.878		2.41
Sakamoto et al. ^[32]	1.686	0.377	7.540	0.684	0.494		2.32
Risnes et al. ^[3]	2.876	1.554	5.324	3.364	0.001		5.43
Dial et al. ^[12]	3.750	0.853	16.477	1.750	0.080		2.36
Colombier et al. ^[11]	1.128	0.493	2.585	0.286	0.775		4.45
Wouters et al. ^[36]	0.258	0.016	4.280	-0.945	0.345		0.85
Sá et al. ^[30]	5.355	2.336	12.271	3.966	0.000		4.45
Sá et al. ^[31]	0.680	0.037	12.431	-0.260	0.795		0.80
Ridderstolpe et al. ^[27]	6.787	4.118	11.186	7.513	0.000		5.99
Newman et al. ^[25]	3.348	1.632	6.868	3.296	0.001		4.94
Tiveron et al. ^[35]	1.935	0.457	8.199	0.896	0.370		2.44
Filsoufi et al. ^[16]	2.934	1.748	4.924	4.074	0.000		5.90
López Gude et al. ^[22]	2.903	1.706	4.939	3.931	0.000		5.84
Baillet et al. ^[9]	1.174	0.855	1.611	0.989	0.322		6.79
Bitkover et al. ^[1]	3.220	0.946	10.962	1.871	0.061		3.01
Braxton et al. ^[10]	2.565	1.852	3.553	5.670	0.000		6.76
Diez et al. ^[13]	2.929	1.422	6.035	2.914	0.004		4.92
Hallam et al. ^[20]	0.839	0.358	1.968	-0.403	0.687		4.35
San Juan et al. ^[33]	8.225	2.017	33.533	2.939	0.003		2.53
Rosmarakis et al. ^[29]	1.467	0.059	36.435	0.234	0.815		0.67
Gummert et al. ^[19]	1.110	0.580	2.125	0.315	0.753		5.27
Manganas et al. ^[23]	160.000	14.472	1768.928	4.140	0.000		1.11
	2.419	1.837	3.184	6.298	0.000		

CI: Confidence interval; OR: 2.4; 95% CI: 1.8-3.1; Z value=6.2; p=0.00; heterogeneity: Q value=79.79; df: 25; p=0.00; I²: 68.67%.

Declaration of conflicting interests

The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Funding

The authors received no financial support for the research and/or authorship of this article.

REFERENCES

1. Bitkover CY, Gårdlund B. Mediastinitis after cardiovascular operations: a case-control study of risk factors. *Ann Thorac Surg* 1998;65:36-40.
2. Antunes PE, Bernardo JE, Eugénio L, de Oliveira JF, Antunes MJ. Mediastinitis after aorto-coronary bypass surgery. *Eur J Cardiothorac Surg* 1997;12:443-9.
3. Risnes I, Abdelnoor M, Almdahl SM, Svennevig JL. Mediastinitis after coronary artery bypass grafting risk factors and long-term survival. *Ann Thorac Surg* 2010;89:1502-9.
4. Parissis H, Al-Alao B, Soo A, Orr D, Young V. Risk analysis and outcome of mediastinal wound and deep mediastinal wound infections with specific emphasis to omental transposition. *J Cardiothorac Surg* 2011;6:111.
5. Floros P, Sawhney R, Vrtik M, Hinton-Bayre A, Weimers P, Senewiratne S, et al. Risk factors and management approach for deep sternal wound infection after cardiac surgery at a tertiary medical centre. *Heart Lung Circ* 2011;20:712-7.
6. Moher D, Liberati A, Tetzlaff J, Altman DG for PRISMA group. Preferred reporting items for systematic reviews and meta-analysis: the PRISMA statement. *BMJ* 2009;339:332-6.
7. Abboud CS, Wey SB, Baltar VT. Risk factors for mediastinitis after cardiac surgery. *Ann Thorac Surg* 2004;77:676-83.
8. Dodds Ashley ES, Carroll DN, Engemann JJ, Harris AD, Fowler VG Jr, Sexton DJ, et al. Risk factors for postoperative

- mediastinitis due to methicillin-resistant *Staphylococcus aureus*. *Clin Infect Dis* 2004;38:1555-60.
9. Baillot R, Cloutier D, Montalin L, Côté L, Lellouche F, Houde C, et al. Impact of deep sternal wound infection management with vacuum-assisted closure therapy followed by sternal osteosynthesis: a 15-year review of 23,499 sternotomies. *Eur J Cardiothorac Surg* 2010;37:880-7.
 10. Braxton JH, Marrin CA, McGrath PD, Ross CS, Morton JR, Norotsky M, et al. Mediastinitis and long-term survival after coronary artery bypass graft surgery. *Ann Thorac Surg* 2000;70:2004-7.
 11. Colombier S, Kessler U, Ferrari E, von Segesser LK, Berdajs DA. Influence of deep sternal wound infection on long-term survival after cardiac surgery. *Med Sci Monit* 2013;19:668-73.
 12. Dial S, Nguyen D, Menzies D. Autotransfusion of shed mediastinal blood: a risk factor for mediastinitis after cardiac surgery? Results of a cluster investigation. *Chest* 2003;124:1847-51.
 13. Diez C, Koch D, Kuss O, Silber RE, Friedrich I, Boergermann J. Risk factors for mediastinitis after cardiac surgery - a retrospective analysis of 1700 patients. *J Cardiothorac Surg* 2007;2:23.
 14. Eklund AM, Lyytikäinen O, Klemets P, Huotari K, Anttila VJ, Werkkala KA, et al. Mediastinitis after more than 10,000 cardiac surgical procedures. *Ann Thorac Surg* 2006;82:1784-9.
 15. Elenbaas TW, Soliman Hamad MA, Schönberger JP, Martens EJ, van Zundert AA, van Straten AH. Preoperative atrial fibrillation and elevated C-reactive protein levels as predictors of mediastinitis after coronary artery bypass grafting. *Ann Thorac Surg* 2010;89:704-9.
 16. Filsofi F, Castillo JG, Rahmanian PB, Broumand SR, Silvay G, Carpentier A, et al. Epidemiology of deep sternal wound infection in cardiac surgery. *J Cardiothorac Vasc Anesth* 2009;23:488-94.
 17. Ghotaslou R, Yagoubi AR, Khalili AA, Mahmodian R. Ghotaslou R, Yagoubi AR, Khalili AA, Mahmodian R. *Jpn J Infect Dis* 2008;61:318-20.
 18. Gualis J, Flórez S, Tamayo E, Alvarez FJ, Castrodeza J, Castaño M. Risk factors for mediastinitis and endocarditis after cardiac surgery. *Asian Cardiovasc Thorac Ann* 2009;17:612-6.
 19. Gummert JF, Barten MJ, Hans C, Kluge M, Doll N, Walther T, et al. Mediastinitis and cardiac surgery--an updated risk factor analysis in 10,373 consecutive adult patients. *Thorac Cardiovasc Surg* 2002;50:87-91.
 20. Hallam J, Skillington P, Law SS, Nordstrand I, Tatoulis J. A Review of deep sternal wound infection rates and prevention practices in cardiac surgery. *Heart, Lung and Circulation* 2011;20:250-284
 21. Lin CH, Hsu RB, Chang SC, Lin FY, Chu SH. Poststernotomy mediastinitis due to methicillin-resistant *Staphylococcus aureus* endemic in a hospital. *Clin Infect Dis* 2003;37:679-84.
 22. López Gude MJ, San Juan R, Aguado JM, Maroto L, López-Medrano F, Cortina Romero JM, et al. Case-control study of risk factors for mediastinitis after cardiovascular surgery. *Infect Control Hosp Epidemiol* 2006;27:1397-400.
 23. Manganas H, Lacasse Y, Bourgeois S, Perron J, Dagenais F, Maltais F. Postoperative outcome after coronary artery bypass grafting in chronic obstructive pulmonary disease. *Can Respir J* 2007;14:19-24.
 24. Muñoz P, Menasalvas A, Bernaldo de Quirós JC, Desco M, Vallejo JL, Bouza E. Postsurgical mediastinitis: a case-control study. *Clin Infect Dis* 1997;25:1060-4.
 25. Newman LS, Szczukowski LC, Bain RP, Perlino CA. Suppurative mediastinitis after open heart surgery. A case control study of risk factors. *Chest* 1988;94:546-53.
 26. Salehi Omran A, Karimi A, Ahmadi SH, Davoodi S, Marzban M, Movahedi N, et al. Superficial and deep sternal wound infection after more than 9000 coronary artery bypass graft (CABG): incidence, risk factors and mortality. *BMC Infect Dis* 2007;7:112.
 27. Ridderstolpe L, Gill H, Granfeldt H, Ahlfeldt H, Rutberg H. Superficial and deep sternal wound complications: incidence, risk factors and mortality. *Eur J Cardiothorac Surg* 2001;20:1168-75.
 28. Robinson PJ, Billah B, Leder K, Reid CM; ASCTS Database Committee. Factors associated with deep sternal wound infection and haemorrhage following cardiac surgery in Victoria. *Interact Cardiovasc Thorac Surg* 2007;6:167-71.
 29. Rosmarakis ES, Prapas SN, Rellos K, Michalopoulos A, Samonis G, Falagas ME. Nosocomial infections after off-pump coronary artery bypass surgery: frequency, characteristics, and risk factors. *Interact Cardiovasc Thorac Surg* 2007;6:759-67.
 30. Sá MP, Soares EF, Santos CA, Figueiredo OJ, Lima RO, Escobar RR, et al. Risk factors for mediastinitis after coronary artery bypass grafting surgery. *Rev Bras Cir Cardiovasc* 2011;26:27-35.
 31. Sá MP, Soares EF, Santos CA, Figueiredo OJ, Lima RO, Escobar RR, et al. Skeletonized left internal thoracic artery is associated with lower rates of mediastinitis in diabetic patients. *Rev Bras Cir Cardiovasc* 2011;26:183-9.
 32. Sakamoto H, Fukuda I, Oosaka M, Nakata H. Risk factors and treatment of deep sternal wound infection after cardiac operation. *Ann Thorac Cardiovasc Surg* 2003;9:226-32.
 33. San Juan R, Chaves F, López Gude MJ, Díaz-Pedroche C, Otero J, Cortina Romero JM, et al. *Staphylococcus aureus* poststernotomy mediastinitis: description of two distinct acquisition pathways with different potential preventive approaches. *J Thorac Cardiovasc Surg* 2007;134:670-6.
 34. Stähle E, Tammelin A, Bergström R, Hambreus A, Nyström SO, Hansson HE. Sternal wound complications--incidence, microbiology and risk factors. *Eur J Cardiothorac Surg* 1997;11:1146-53.
 35. Tiveron MG, Fiorelli AI, Mota EM, Mejia OA, Brandão CM, Dallan LA, et al. Preoperative risk factors for mediastinitis after cardiac surgery: analysis of 2768 patients. *Rev Bras Cir Cardiovasc* 2012;27:203-10.
 36. Wouters R, Wellens F, Vanermen H, De Geest R, Degrieck I, De Meerleer F. Sternotomy and mediastinitis after coronary artery bypass grafting. Analysis of risk factors. *Tex Heart Inst J* 1994;21:183-8.
 37. Kluge RM, Calia FM, McLaughlin JS, Hornick RB. Sources of contamination in open heart surgery. *JAMA* 1974;230:1415-8.

38. Kansy A, Jacobs JP, Pastuszko A, Mirkowicz-Matek M, Manowska M, Jezierska E, et al. Major infection after pediatric cardiac surgery: external validation of risk estimation model. *Ann Thorac Surg* 2012;94:2091-5.
39. Chen LF, Arduino JM, Sheng S, Muhlbaier LH, Kanafani ZA, Harris AD, et al. Epidemiology and outcome of major postoperative infections following cardiac surgery: risk factors and impact of pathogen type. *Am J Infect Control* 2012;40:963-8.
40. Spelman DW, Russo P, Harrington G, Davis BB, Rabinov M, Smith JA, et al. Risk factors for surgical wound infection and bacteraemia following coronary artery bypass surgery. *Aust N Z J Surg* 2000;70:47-51.
41. Maile MD, Engoren MC, Tremper KK, Jewell E, Khetarpal S. Worsening preoperative heart failure is associated with mortality and noncardiac complications, but not myocardial infarction after noncardiac surgery: a retrospective cohort study. *Anesth Analg* 2014;119:522-32.
42. Kadija S, Stefanović A, Jeremić K, Tavcar J, Argirović R, Pantović S. Malignant disease as a risk factor for surgical site infection. *Clin Exp Obstet Gynecol* 2012;39:53-6.